Evidence map›Paper›PMID 36384966›Full record

ArticleSchizophrenia (Heidelberg, Germany)2022

Neurocognitive moderation of repetitive transcranial magnetic stimulation (rTMS) effects on cannabis use in schizophrenia: a preliminary analysis.

Samantha Johnstone, Darby J E Lowe, Karolina Kozak-Bidzinski, Marcos Sanches, David J Castle, Jennifer S Rabin, Rachel A Rabin, Tony P George

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03189810 (Effects of Repetitive Transcranial Magnetic Stimulation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03189810 nacompletednot on this map

Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia

TypeinterventionalSponsorCentre for Addiction and Mental HealthRan2017 to 2021Enrolled24ConditionsRepetitive Transcranial Magnetic Stimulation (rTMS), Schizophrenia, Cannabis Use Disorder, CognitionArmsRepetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (rTMS), Weekly Counselling Session
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Samantha Johnstone *Centre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, M6G 1H4, Canada.ORCID http://orcid.org/0000-0002-5459-265X
Darby J E Lowe *Centre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, M6G 1H4, Canada.
Karolina Kozak-BidzinskiCentre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, M6G 1H4, Canada.
Marcos SanchesCentre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, M6G 1H4, Canada.ORCID http://orcid.org/0000-0001-9075-1761
David J CastleCentre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, M6G 1H4, Canada.
Jennifer S RabinDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.
Rachel A RabinDepartment of Psychiatry, McGill University, Montreal, QC, Canada.
Tony P GeorgeCentre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, M6G 1H4, Canada. tony.george@camh.ca.ORCID http://orcid.org/0000-0003-1645-9767
Centre for Addiction and Mental Health · CAMcGill University · CASunnybrook Health Science Centre · CA

Funding

Effects of rTMS on Cannabis Use and Cognitive Outcomes in SchizophreniaR21DA043949 · NIDA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI GEORGE, TONY P · 2017 to 2018
$286k
NIDA NIH HHS R21 DA043949U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) R21-DA-043949
6 · The paper itself

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment for cannabis use disorder in schizophrenia; however, gaps in the literature remain as to the potential role of neurocognitive functioning in treatment response. We evaluated the moderating role of select cognitive functions including baseline executive functioning, verbal memory, and sustained attention, and we explore the mediating role of changes in task performance on changes in cannabis use in both active and sham rTMS groups. Participants underwent high-frequency (20 Hz) rTMS applied to the bilateral dorsolateral prefrontal cortex 5x/week for 4 weeks. Weekly self-report of cannabis use and semi-quantitative urinary carboxy-tetrahydrocannabinol levels were recorded. A neurocognitive battery assessing verbal memory, visuospatial working memory, verbal working memory, sustained attention, delayed discounting, and complex planning was administered pre- and post-treatment. Better baseline performance on tasks assessing sustained attention, delayed discounting, and complex planning moderated the extent to which participants in the active group reduced cannabis use. There were no significant indirect pathways between treatment, changes in neuropsychological performance, and changes in cannabis use; however, active rTMS improved complex planning and sustained attention. These preliminary findings suggest that there is a moderating role of sustained attention, delayed discounting, and complex planning on the effects of rTMS on cannabis use. Further, mediation models suggest rTMS may exert direct effects on cannabis use independent of its effects on cognitive functioning in people with SCZ. Trial Registration: clinicaltrials.gov: NCT03189810.

Identifiers

PMID36384966
PMCPMC9668838
OpenAlexW4309389331

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.